Cancer treatments are evolving, with increasing focus on using the body’s immune defenses to combat the disease. Reetta Virtakoivu, Senior Scientist at Orion, explains how immunotherapy works and why it holds promise for more cancer patients in the future. What…
Versant Ventures has announced the launch of Pep2Tango Therapeutics Inc., a new startup focused on next-generation weight loss treatments. The company will use funds from a significant, undisclosed investment round to advance the development of its innovative unimolecular tetra-receptor agonist…
Altasciences is pleased to have supported Metsera, Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation treatments for obesity and metabolic diseases, in its nonclinical and early-stage clinical trials. This partnership includes a recent Phase I/II trial of MET-097i, an…
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene fusions or rearrangements, who have experienced progression after chemotherapy. The…
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their vulnerability, children often lack access to age-appropriate medications due to…
Bayer and Cytokinetics, Inc. (Nasdaq: CYTK) have announced a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan. Aficamten is a cardiac myosin inhibitor being developed for the potential treatment of obstructive and non-obstructive hypertrophic…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., has announced a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. to resolve patent litigation…
UCB and Biogen have unveiled detailed Phase 3 results for dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant improvements in managing moderate-to-severe systemic lupus erythematosus (SLE). Findings from the PHOENYCS GO study were presented as a late-breaking…
CVS Health® (NYSE: CVS) announced the addition of four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. These appointments follow collaborative discussions with Glenview Capital Management. “Our discussions with Glenview have reinforced…
Hansoh Pharmaceutical Group Co., Ltd. (03692.HK) announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to Inebilizumab for the treatment of Immunoglobulin G4-related disease (IgG4-RD). This designation follows positive results from the Global Phase 3 MITIGATE study, which…
A team of Nigerian researchers and clinicians, led by Aminu Kano Teaching Hospital, has made significant progress in understanding maternal and newborn health through a groundbreaking data initiative. In collaboration with the World Health Organization, the Nigerian Federal Ministry of…
Alnylam Pharmaceuticals (Nasdaq: ALNY) presented encouraging Phase 1 results for nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic for transthyretin (ATTR) amyloidosis, at the American Heart Association Scientific Sessions 2024 in Chicago. The data revealed that a single dose of nucresiran…
